CRISPR-Cas9

CRISPR-Cas9
Deposition authors: Nishimasu, H., Ishitani, R., Nureki, O.; Visualization autho · CC0 · source
Name	CRISPR-Cas9
Classification	Genome editing system
Discovered	2012
Developers	Emmanuelle Charpentier, Jennifer Doudna
Organisms	Bacteria, Archaea
Applications	Research, Medicine, Agriculture, Biotechnology

CRISPR-Cas9 is a programmable genome editing system derived from adaptive immune systems in prokaryotes that enables targeted modification of DNA sequences in diverse organisms. First harnessed for directed DNA cleavage in 2012 by researchers working across institutions such as the University of California, Berkeley, Max Planck Institute for Infection Biology, and the University of Vienna, the technology rapidly influenced projects at laboratories including Broad Institute, Salk Institute, Harvard University, MIT, and Stanford University. Its emergence reshaped work at organizations such as Novartis, Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics and featured in policy debates involving bodies like the National Institutes of Health, European Commission, World Health Organization, and U.S. Food and Drug Administration.

History and discovery

Early descriptions of clustered regularly interspaced short palindromic repeats arose from genomic surveys by groups at Mitsubishi Heavy Industries collaborators and teams including Francisco Mojica at the University of Alicante. Characterization of CRISPR arrays involved work from researchers at Los Alamos National Laboratory, Pasteur Institute, and University of Otago. The role of associated Cas proteins was elucidated by investigators at Cleveland Clinic, University of Tokyo, and University of São Paulo. The transformative adaptation of a single-guide RNA to program a Cas9 endonuclease was demonstrated in experiments led by Emmanuelle Charpentier and Jennifer Doudna, with parallel rapid applications published by groups at the Broad Institute (notably Feng Zhang) and teams affiliated with Zhang Lab and George Church at Harvard Medical School. Institutional milestones included patent filings by Broad Institute and University of California, legal disputes adjudicated in venues involving U.S. Patent and Trademark Office, and recognition via awards such as the Nobel Prize in Chemistry and Breakthrough Prize.

Mechanism and molecular components

The system harnesses RNA-guided DNA endonucleases; studies from Columbia University, Yale University, University of Cambridge, Max Planck Society, and European Molecular Biology Laboratory detailed components including Cas9 proteins, guide RNAs, and protospacer adjacent motifs recognized by laboratories like Cold Spring Harbor Laboratory and Karolinska Institutet. Structural biology efforts at Lawrence Berkeley National Laboratory, Brookhaven National Laboratory, and Diamond Light Source revealed conformations of Cas9 from species such as Streptococcus pyogenes and Staphylococcus aureus; cryo-EM and X-ray crystallography work by teams at University of Oxford and ETH Zurich clarified R-loop formation and nuclease domains similar to discoveries at Max Planck Institute for Biophysical Chemistry. Biochemical characterization by researchers at Johns Hopkins University, University of Pennsylvania, and University of California, San Diego showed DNA double-strand break induction, non-homologous end joining, and homology-directed repair, informing modifications implemented by companies like Beam Therapeutics and research centers such as Fred Hutchinson Cancer Research Center.

Genome editing applications

Laboratories at Massachusetts General Hospital, Children's Hospital of Philadelphia, and Seattle Children's Research Institute applied the system for disease models, while agricultural projects at Monsanto and DuPont inspired work at Wageningen University, University of California, Davis, and Chinese Academy of Agricultural Sciences. Clinical translation progressed through trials sponsored by Vertex Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, and academic consortia at University College London and University of Pennsylvania Hospital. Model organism research involved groups at Max Planck Institute for Developmental Biology, Sanger Institute, Cold Spring Harbor Laboratory, and Wellcome Trust facilities working on mice, zebrafish, fruit flies, and plants. Conservation and synthetic biology initiatives at The Nature Conservancy, Ginkgo Bioworks, and Ecoshift explored gene drives and pathway engineering, while industrial biotechnology labs at BASF and Syngenta investigated trait improvement and metabolic engineering.

Delivery methods and technical challenges

Delivery research by teams at MIT, Harvard Medical School, University of Pennsylvania, Stanford University School of Medicine, and UCSF contrasted viral vectors such as adeno-associated virus studied at Children's Hospital of Philadelphia and lentiviral systems developed by Novartis with nonviral methods from Wyss Institute, SRI International, MIT Media Lab, and Lawrence Livermore National Laboratory. Nanoparticle platforms advanced by Alnylam Pharmaceuticals and Moderna intersected with electroporation protocols used at Imperial College London and microinjection techniques refined at European Molecular Biology Laboratory. Technical challenges identified by consortia at National Human Genome Research Institute, Wellcome Sanger Institute, and European Bioinformatics Institute include editing efficiency, mosaicism, immune responses cataloged by researchers at National Institute of Allergy and Infectious Diseases and delivery specificity pursued by DARPA and Defense Advanced Research Projects Agency partners.

Ethical, legal, and social implications

Bioethics scholarship from Harvard Kennedy School, Oxford University Centre for Ethics, and Princeton University engaged stakeholders including UNESCO, World Health Organization, European Parliament, and national academies like the National Academy of Sciences and Royal Society. High-profile controversies involved researchers connected to institutions such as Southern University of Science and Technology, Sun Yat-sen University, and Shenzhen Institutes of Advanced Technology, prompting summit meetings hosted by UC Berkeley and policy statements from NIH and European Commission. Legal and intellectual property debates implicated U.S. Supreme Court adjudications, patent offices including European Patent Office, and industry groups like BIO and PhRMA. Social impact discussions at TED, Aspen Institute, and World Economic Forum addressed access, equity, and governance, while regulatory frameworks at FDA, EMA, and national ministries influenced clinical and agricultural deployment.

Safety, off-target effects, and regulation

Research on specificity by teams at Broad Institute, Wellcome Sanger Institute, Stanford Genome Technology Center, Carnegie Institution for Science, and National Institutes of Health developed methods such as GUIDE-seq and CIRCLE-seq originating from collaborations including University of Utah and University of Copenhagen. Mitigation strategies evaluated by Zhejiang University, Peking University, and Tata Institute of Fundamental Research include high-fidelity Cas9 variants engineered at Harvard University and base editing approaches commercialized by Beam Therapeutics and studied at University of California, San Francisco. Regulatory oversight has been exercised by agencies such as U.S. Food and Drug Administration, European Medicines Agency, China Food and Drug Administration, and advisory bodies including National Academies of Sciences, Engineering, and Medicine. Ongoing surveillance and post-approval monitoring protocols have been implemented by institutions such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, and global consortia convened by the World Health Organization.

Category:Genome editing